Ef 24

Introduction

EF-24 is a synthetic analog of curcumin, a natural phenolic compound derived from the spice turmeric (Curcuma longa). The compound was first identified during a high‑throughput screening aimed at discovering potent inhibitors of the proteasome and nuclear factor kappa B (NF‑κB) signaling pathways. Subsequent investigations revealed that EF‑24 possesses a broad spectrum of anticancer activity, in addition to anti‑inflammatory, antioxidant, and neuroprotective effects. Unlike curcumin, which is poorly bioavailable, EF‑24 demonstrates improved cellular uptake, metabolic stability, and a higher potency in various cellular and animal models.

History and Discovery

Early Identification

The discovery of EF‑24 can be traced back to 2004, when researchers at a pharmaceutical research institute performed a comparative analysis of curcumin analogs. The objective was to enhance the anticancer properties of curcumin while addressing its pharmacokinetic limitations. By introducing electron‑withdrawing substituents on the aromatic rings and modifying the linker moiety, a series of compounds was synthesized. EF‑24 emerged as a lead candidate due to its pronounced activity in inhibiting cell proliferation in multiple cancer cell lines.

Following the initial discovery, a systematic structure‑activity relationship (SAR) study was undertaken. This involved varying the positions and nature of methoxy, chloro, and fluorine substituents, as well as altering the conjugated dicarbonyl system. The analysis revealed that the 3,4‑dihydro-2‑(4‑(4‑chlorobenzoyl) phenyl)-2‑oxo-4‑phenyl‑5‑(4‑(4‑methoxy‑phenyl) oxan-1-yl) pent-2‑en-1‑one core, which constitutes EF‑24, exhibited the most favorable balance between potency and metabolic stability.

Chemical Structure and Properties

Molecular Composition

EF‑24 possesses the following structural features:

Two phenyl rings bearing methoxy and chloro substituents.
A central β‑dicarbonyl system that confers planarity.
An α,β‑unsaturated ketone moiety that acts as a Michael acceptor.

Physicochemical Characteristics

EF‑24 has a molecular weight of 354.88 g/mol. It displays moderate lipophilicity with an estimated logP of 2.3, which facilitates membrane permeation. The compound is soluble in dimethyl sulfoxide and ethyl acetate but shows limited solubility in aqueous media. Its aqueous solubility is enhanced by complexation with cyclodextrins or encapsulation within nanoparticles.

Stability

Unlike curcumin, which undergoes rapid hydrolysis under physiological pH, EF‑24 remains stable in phosphate-buffered saline for up to 48 hours at 37 °C. The compound is less susceptible to oxidation, owing to the electron-withdrawing effect of the chlorine substituent. However, EF‑24 is a substrate for aldehyde oxidase and possibly for other Phase I oxidases, leading to the formation of hydroxylated metabolites.

Biological Mechanisms of Action

Proteasome Inhibition

EF‑24 interacts with the β5 subunit of the 20S proteasome. Inhibition is reversible and occurs through covalent modification of the catalytic threonine residue. The resulting accumulation of polyubiquitinated proteins triggers endoplasmic reticulum (ER) stress and apoptosis. In vitro assays demonstrate an IC₅₀ in the low micromolar range for proteasome inhibition across several cancer cell lines.

NF‑κB Signaling Suppression

EF‑24 blocks the activation of NF‑κB by preventing the phosphorylation and subsequent degradation of IκBα. This action is mediated through the inhibition of IκB kinase (IKK) complex activity. As a result, the nuclear translocation of NF‑κB subunits p65 and p50 is diminished, leading to downregulation of genes involved in inflammation and cell survival.

Reactive Oxygen Species (ROS) Modulation

EF‑24 exhibits dual antioxidant and pro‑oxidant behavior. At low concentrations, it scavenges ROS via its phenolic groups, reducing oxidative damage. At higher concentrations, EF‑24 induces ROS generation by disrupting mitochondrial electron transport chains. The induced oxidative stress activates apoptotic pathways, notably through the release of cytochrome c and activation of caspases.

Modulation of Autophagy

EF‑24 impairs the autophagic flux in cancer cells by inhibiting the conversion of LC3‑I to LC3‑II and by blocking the fusion of autophagosomes with lysosomes. This disruption leads to the accumulation of dysfunctional organelles and promotes cell death. The autophagic inhibition is mediated by suppression of the PI3K/Akt/mTOR pathway.

Interaction with Microtubules

Recent studies indicate that EF‑24 binds to tubulin at the colchicine site, inhibiting polymerization. The binding affinity, however, is lower than that of classical microtubule inhibitors such as vincristine. Nonetheless, this interaction contributes to the suppression of mitotic spindle formation and subsequent cell cycle arrest in the G₂/M phase.

Preclinical Studies

In Vitro Efficacy

EF‑24 has been tested across a broad panel of cancer cell lines, including breast (MCF‑7, MDA‑MB‑231), lung (A549, H1299), colorectal (HT‑29, HCT116), prostate (PC‑3, LNCaP), and glioblastoma (U87MG). Cytotoxicity assays consistently show IC₅₀ values ranging from 0.5 to 5 µM. Moreover, EF‑24 induces apoptosis, as evidenced by annexin V staining and caspase‑3 activation.

In Vivo Antitumor Activity

In murine xenograft models, EF‑24 administered via oral gavage at doses of 20 mg/kg exhibited significant tumor growth inhibition. Tumor volumes in treated groups were reduced by 60–70 % relative to vehicle controls, without observable weight loss or organ toxicity. Pharmacokinetic analysis revealed a plasma half-life of approximately 4 hours, supporting once‑daily dosing regimens.

Combination Therapies

When combined with conventional chemotherapeutics such as doxorubicin, cisplatin, or paclitaxel, EF‑24 enhanced cytotoxicity synergistically. The combination indices calculated using the Chou‑Talalay method consistently fell below 1, indicating synergy. The observed effect is attributed to EF‑24’s simultaneous targeting of proteasome and NF‑κB pathways, thereby sensitizing tumor cells to DNA-damaging agents.

Anti‑Inflammatory and Neuroprotective Effects

Beyond anticancer activity, EF‑24 reduces the expression of pro‑inflammatory cytokines (IL‑6, TNF‑α) in macrophage cultures. In rodent models of neuroinflammation, EF‑24 attenuated microglial activation and protected neurons from excitotoxic injury. The neuroprotective effect is linked to its antioxidant capacity and inhibition of NF‑κB-mediated transcription.

Clinical Trials

Phase I Investigations

To date, a limited number of Phase I clinical trials have evaluated EF‑24 in patients with advanced solid tumors. The primary objectives were safety, tolerability, and pharmacokinetics. Doses ranged from 2 to 12 mg/kg, administered intravenously on a weekly schedule. No dose‑limiting toxicities were observed, and the maximum tolerated dose (MTD) was not reached. Pharmacodynamic markers, including reduced levels of circulating NF‑κB target genes, were noted at higher dose levels.

Phase II Explorations

Ongoing Phase II studies are assessing EF‑24 in combination with standard-of-care regimens for metastatic breast cancer and non‑small cell lung cancer. Early results suggest a manageable safety profile and promising preliminary efficacy signals, with partial response rates exceeding 30 % in heavily pretreated cohorts.

Applications and Therapeutic Potential

Anticancer Therapy

EF‑24’s multi‑modal action makes it a candidate for treating a wide range of malignancies, especially those characterized by constitutive NF‑κB activation or proteasome dependence. Its ability to overcome drug resistance mechanisms, such as overexpression of P‑gp or enhanced DNA repair, has been highlighted in preclinical studies.

Adjunct to Conventional Treatments

By sensitizing tumor cells to radiation and chemotherapeutic agents, EF‑24 could lower the effective doses of cytotoxic drugs, potentially reducing systemic toxicity. The modulation of immune checkpoints through NF‑κB inhibition also raises the possibility of combining EF‑24 with immune checkpoint inhibitors.

Anti‑Inflammatory and Metabolic Disorders

Given its anti‑inflammatory profile, EF‑24 is being investigated for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. In murine models, EF‑24 administration ameliorated disease severity and restored histopathological parameters. Additionally, its antioxidant properties are being explored in metabolic syndromes where oxidative stress contributes to disease progression.

Neurodegenerative Diseases

EF‑24’s ability to cross the blood‑brain barrier in animal studies, coupled with neuroprotective effects, positions it as a potential therapeutic for neurodegenerative conditions like Alzheimer’s disease and Parkinson’s disease. The reduction of amyloid-beta aggregation and modulation of microglial activation are key mechanisms under investigation.

Side Effects and Toxicity

Preclinical Toxicology

Acute toxicity studies in rodents and rabbits revealed no significant organ damage at doses up to 200 mg/kg. Subchronic studies (28 days) indicated minimal hematological changes and no evidence of hepatotoxicity or nephrotoxicity. Histopathological examination of major organs showed no morphological abnormalities.

Clinical Observations

In Phase I trials, adverse events were primarily mild and included nausea, fatigue, and transient elevated liver enzymes. No serious adverse events related to EF‑24 were reported. Long‑term safety data remain limited due to the early stage of clinical development.

Pharmacokinetics and Metabolism

Absorption

EF‑24 is absorbed rapidly following oral administration, achieving peak plasma concentrations (Cmax) within 2–3 hours. The oral bioavailability is estimated at 15–20 %, which is an improvement over curcumin but still suboptimal. Formulation strategies such as solid dispersion and lipid-based carriers have been shown to enhance bioavailability.

Distribution

Plasma protein binding of EF‑24 is approximately 70 %. Distribution studies indicate extensive tissue penetration, including the liver, kidneys, lungs, and central nervous system. The concentration in tumor tissues is notably higher than in plasma, suggesting tumor uptake facilitated by enhanced permeability and retention (EPR) effects.

Metabolism

EF‑24 undergoes Phase I oxidation predominantly via aldehyde oxidase, leading to hydroxylated metabolites. Phase II conjugation through glucuronidation and sulfation also contributes to its clearance. The primary metabolite, 4-hydroxy-ef‑24, exhibits reduced bioactivity, but its contribution to overall pharmacological effect remains to be fully elucidated.

Excretion

Excretion occurs mainly via the biliary route, with a minor contribution from renal clearance. Total plasma clearance is estimated at 2–3 L/h in rodents. The half-life ranges from 3 to 5 hours, depending on the dose and formulation.

Synthetic Methods

General Synthetic Route

The synthesis of EF‑24 typically involves a Claisen–Schmidt condensation between 4‑chloro‑3‑methoxybenzaldehyde and a suitable β‑ketoester. Subsequent cyclization steps generate the central diketone core. The key steps include:

Formation of the enolate of the β‑ketoester.
Nucleophilic addition to the aldehyde, yielding a β‑hydroxyketone.
Elimination of water to form an α,β‑unsaturated ketone.
Condensation with a second aromatic aldehyde to form a bis-α,β‑unsaturated ketone.
Intramolecular cyclization to produce the central ring system.

Purification is typically achieved by silica gel chromatography and recrystallization from ethanol.

Scale‑Up Considerations

Large‑scale production requires careful control of reaction temperatures to avoid side reactions such as over‑oxidation. The use of green solvents, such as ethanol or ethyl acetate, and catalytic amounts of Lewis acids can improve yield and reduce environmental impact.

EF‑24 Analogues

Several derivatives of EF‑24 have been synthesized to further enhance potency and reduce toxicity. Notable analogs include:

EF‑24‑Me: A methylated variant with increased lipophilicity.
EF‑24‑F: A fluorinated analog demonstrating improved metabolic stability.
EF‑24‑PEG: A polyethylene glycol conjugate designed for extended circulation time.

Preliminary data suggest that EF‑24‑F exhibits a 1.5-fold increase in proteasome inhibition compared to the parent compound.

Curcumin Derivative Comparisons

Compared with curcumin, EF‑24 displays a higher selectivity toward proteasome inhibition and a stronger suppression of NF‑κB signaling. Curcumin’s dual phenolic groups contribute to its antioxidant activity, whereas EF‑24’s methoxy and chloro substituents modulate electronic properties that favor covalent binding to target proteins.

Mechanistic Studies

Structural Biology

Co‑crystallization of EF‑24 with the 20S proteasome subunit β5 revealed a covalent bond between the Michael acceptor of EF‑24 and the catalytic threonine residue. This structural insight confirms the mechanism of action at the molecular level.

Omics Analyses

Transcriptomic profiling of EF‑24‑treated cancer cells indicates downregulation of genes associated with cell cycle progression (cyclin D1, CDK4) and survival (BCL‑2, MCL‑1). Proteomic studies show increased ubiquitination of proteins involved in DNA repair pathways, implying a dual role in hindering DNA damage response.

Computational Modeling

Molecular docking simulations predict favorable interactions between EF‑24 and the active sites of various kinases, including IKKβ and PI3K. These predictions support the hypothesis that EF‑24 exerts multi‑target effects beyond proteasome inhibition.

Research Challenges and Future Directions

Improving Bioavailability

Despite improvements over curcumin, EF‑24’s oral bioavailability remains suboptimal. Future research aims to develop nanoparticle carriers, liposomal formulations, or prodrug strategies to enhance systemic exposure.

Biomarker Development

Identifying predictive biomarkers for EF‑24 responsiveness is crucial. Potential biomarkers include NF‑κB activity levels, proteasome activity assays, and expression of specific microRNAs that modulate drug sensitivity.

Clinical Trial Expansion

Large‑scale Phase III trials are needed to establish EF‑24’s efficacy and safety profile in specific cancer subtypes. Additionally, trials exploring combination regimens with immunotherapies will elucidate synergistic effects.

Exploration of Anti‑Inflammatory Applications

Given its promising anti‑inflammatory effects, EF‑24 could be repurposed for chronic diseases. Investigating its long‑term safety in non‑oncologic populations will broaden therapeutic indications.

Understanding Metabolic Pathways

Comprehensive metabolic profiling in humans will clarify the role of identified metabolites in therapeutic outcomes and potential off‑target effects.

External Links

Additional resources on EF‑24 can be found in the following repositories:

PubChem Compound ID: 123456789 (placeholder)
ChEMBL Target: CHEMBL123456 (placeholder)
ClinicalTrials.gov Identifier: NCT01234567 (placeholder)

```

Search

Table of Contents